Paschke Marko Kornmann Doctor of Medicine, Clinic of General and Visceral Surgery, University of Ulm, Ulm, Germany. <...> Survival of patients with colon and rectal cancer is constantly increasing. <...> In order to further improve prognosis the development of distant metastases after primary tumor resection has to be further reduced. <...> Adjuvant chemotherapy is standard for UICC III colon cancer using fluoropyrimidines or intensified regimens including oxaliplatin. <...> However, many patients receive adjuvant treatment without benefit but suffer from toxicity, in case of oxaliplatin even from life-long chronic neurotoxicity. <...> The aim of this overview is to summarize data for adjuvant treatment of colon and rectal cancer with special focus on UICC substage and age and to discuss points of criticism from a surgical point of view. <...> Adjuvant chemotherapy with 5-fluorouracil (5-FU) and folinic acid (FA) clearly increases survival in colon cancer UICC stage III. <...> Addition of oxaliplatin is especially beneficial for patients with pT3/4pN2 tumors (UICC IIIc). <...> The effects of adjuvant treatment in rectal cancer are less pronounced compared to colon cancer. <...> Paschke 5 years in the presence of distant metastases (UICC stage IV) is still way below 20% among all patients in this subgroup [2]. <...> In order to further improve the prognosis of patients with colon and rectal cancer it is important to further reduce the occurrence of distant metastases after removal of the primary cancer. <...> For example the pre-operative staging was of low intensity and quality (no CT-scan) to detect distant metastases in the above mentioned trial of Moertel and colleagues <...>
Практическая_онкология_№1._Спец._выпуск_2017.pdf
--
--
--
-
-
---
---
-
----
----
--
----
--
----
-
-
-
---
-
---
--
--
-
--
---
-
-
-
--
-
-
Стр.2
--
-
--
--
-
-
-
---
---
----
----
--
----
--
-
----
-
-
-
--
-
-
--
-
--
--
-
--
--
-
-
-
-
-
-
-
--
-
Стр.3